Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

OnKure Therapeutics Q3 2026 Results: Net Loss of $17.8M, Loss Widens

OnKure Therapeutics reported a net loss of $48.3 million for the nine months ended September 30, 2026, compared to $46.0 million in the prior year period. The company significantly strengthened its balance sheet, ending the quarter with $151.4 million in cash and cash equivalents following the issuance of Class A common stock.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-17.8-14.7
EPS (diluted, $ a share)$-0.36$-1.09

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: OKUR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

OnKure Therapeutics, Inc.: key numbers

Share price
$2.75Close, Nov 16
Market cap
$111M
Shares outstanding
40.5MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from OnKure Therapeutics, Inc.

All →
4:11 PM ET 8-K
Financial Results

OnKure Therapeutics Financial Results

OnKure Therapeutics reported third quarter 2026 financial results and provided updates on its PI3Kα pan-mutant-selective inhibitor pipeline. The company remains on track to submit IND applications for OKI-355 (vascular anomalies) and OKI-345 (breast cancer) in the first half of 2027, while also launching the PANORAMA disease registry.

“We continue to advance the development of next-generation PI3Kα pan-mutant-selective inhibitors through our pipeline, including OKI-355 in vascular anomalies and OKI-345 in breast cancer. Both of our lead programs remain on track for IND submissions in the first half of 2027.”

Nicholas Saccomano, Ph.D., President and Chief Executive Officer

“People living with vascular anomalies remain underserved, and we believe OnKure has an opportunity to help shape the future of treatment for this community. Mutations in the PIK3CA gene drive a range of vascular malformations, providing a compelling rationale for our development of OKI-355, which is designed to provide broad coverage across these mutations.”

Samuel Agresta, M.D., Chief Medical Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.